Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07462572

Virtual Twins as Tools for Personalized Clinical Care in Renal Denervation - Pilot Study

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

High blood pressure (hypertension) is a common condition. Despite the availability of several medications, many patients continue to have poorly controlled blood pressure. Renal denervation (RDN), a minimally invasive procedure that reduces overactive kidney nerves, has emerged as a potential treatment for certain patients with difficult-to-control hypertension. However, not all patients benefit from this procedure, and there is currently no reliable way to predict who will respond. The VITAL-RDN study (Virtual twins as tools for personalized clinical care in renal denervation - Pilot study) aims to test whether a "digital twin" can help predict which patients are most likely to respond to renal denervation. A digital twin is a personalized computer model built from an individual patient's clinical, biological, and physiological data. It is designed to simulate how that patient's cardiovascular system functions and how it may respond to treatment. The main objective of this pilot study is to evaluate whether the digital twin can accurately distinguish between patients who will respond to renal denervation and those who will not. A responder is defined as a patient whose daytime systolic blood pressure decreases by at least 5 mmHg three months after the RDN. Three groups of patients will be enrolled: 30 patients with resistant hypertension or other clinical indications for renal denervation. 20 patients with untreated primary hypertension who are starting blood pressure-lowering medication. 10 patients with primary aldosteronism who are scheduled for surgical adrenalectomy. In addition to evaluating prediction of response to renal denervation, the study will also assess the performance of the digital twin in predicting response to antihypertensive medication or adrenalectomy in the respective subgroups. If successful, this approach could support more personalized treatment decisions, reduce unnecessary procedures, and improve blood pressure control by matching the right therapy to the right patient.

Conditions

Interventions

TypeNameDescription
OTHERData collection in order to train the digital twinIn this research, results from routine examinations performed to monitor the patient's health will be used to train the digital twin. These include resting blood pressure and heart rate measurements, vascular assessments (pulse wave velocity, carotid stiffness), electrocardiogram (ECG), echocardiography, extracellular water measurement by bioimpedance, cardiopulmonary exercise testing, and routine blood tests for renal and neurohumoral markers. In addition, the patient's autonomic nervous system will be evaluated using functional tests. The patient will place his or her hand in cold water and squeeze a handgrip device to assess blood pressure and heart rate reactivity (about 20 minutes). The patient will wear a portable device (Calamari) recording heart rhythm, chest vibrations, and blood volume. The patient will also complete questionnaires.

Timeline

Start date
2026-04-01
Primary completion
2028-10-01
Completion
2028-10-01
First posted
2026-03-10
Last updated
2026-03-10

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT07462572. Inclusion in this directory is not an endorsement.

Virtual Twins as Tools for Personalized Clinical Care in Renal Denervation - Pilot Study (NCT07462572) · Clinical Trials Directory